Updates are available Addendum dated 2019-07-02
Click to view Addendum: https://doi.org/10.1038/s41467-019-10892-9
-
Authors
Bessen, Jeffrey L. http://orcid.org/0000-0002-0351-7393
Afeyan, Lena K.
Dančík, Vlado
Koblan, Luke W.
Thompson, David B.
Leichner, Chas
Clemons, Paul A. http://orcid.org/0000-0002-1800-5112
Liu, David R. http://orcid.org/0000-0002-9943-7557
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Biomedical Imaging and Bioengineering (R01 EB022376)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R35 GM118062)
Howard Hughes Medical Institute (Liu investigatorship)
- License Information
-
More Information
Article History
Received: 15 February 2019
Accepted: 5 April 2019
First Online: 26 April 2019
Competing interests
: D.R.L. is a consultant and co-founder of Beam Therapeutics, Editas, and Pairwise Plants, companies that use genome editing. J.L.B., D.B.T., and D.R.L. have filed a patent application on the Rec-seq profiling method. The remaining authors declare no competing interests.
